Accès ouvert déclaré2026supplementary-materials
Supplementary Table S4 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Ben Tran, Mark Voskoboynik, Sang‐We Kim, Charlotte Lemech, Enric Carcereny, Sun Young Rha, Myung‐Ju Ahn, Enriqueta Felip, Ki Hyeong Lee, Eduardo Castañón Álvarez, James Chih‐Hsin Yang, Paolo A. Ascierto, Mariano Provencio, Shunsuke Kondo, Yasutoshi Kuboki, Daniel Freeman, Xuyang Song, Jorge Blando, Steven Eck, Florian Song, Zoey Tang, Michael Kuziora, Shelby D. Gainer, Patrick Mitchell, Julie M. Asare, Amal Ayyoub, Ikbel Achour, Deepa S. Subramaniam, Seock‐Ah Im
0Citations signalées
0Institutions associées
0Pays d’affiliation
Résumé fourni par la source
Supplementary Table S4. Baseline patient demographics and disease characteristics of patients receiving single-agent volrustomig 750 mg in the parallel phase I study in Japanese patients.